Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer

Radiotherapy and Oncology

Volumn 66, Issue 2, 2003, Pages 167-172

  Pellizzon, Antonio Cassio Assis ^a   Nadalin, Wladmir ^b   Salvajoli, João Vitor ^a   Fogaroli, Ricardo Cesar ^a   Novaes, Paulo Eduardo R S ^a   Maia, Maria Aparecida Conte ^a   Ferrigno, Robson ^a  

^a Imaging Department   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute morbidity; Biochemical control; High dose rate brachytherapy; Late morbidity; Prostate cancer

Indexed keywords

ACETIC ACID DERIVATIVE; ANDROGEN; CIPROTERON ACETATE; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BEAM THERAPY; BIOCHEMISTRY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; ECHOGRAPHY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GEOMETRY; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ONLINE SYSTEM; ORGAN SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE; PROSTATE ADENOCARCINOMA; QUALITY CONTROL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SCORING SYSTEM; SEMINAL VESICLE; TREATMENT PLANNING; URINARY TRACT DISEASE;

EID: 0037295445     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(02)00408-5     Document Type: Article

References (34)

1. Cancer facts and figures. 1997;American Cancer Society, Atlanta, GA.
2. Borghede G., Hedelin H., Holmang S., Johansson K.A., Sernbo G., Mercke C. Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Radiother Oncol. 4:(3):1997;245-250.
3. Secretaria Nacional de Assistência à Saúde. Instituto nacional do cancer. Estimtiva de incidência e mortalidade por câncer no Brasil, 2000. 2000;23 INCA, Rio de Janeiro.
4. Brenner D.J., Hall E.J. Fractionation and protraction of radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
5. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
6. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346.
7. Curran M.J., Healey G.A., Bihrle W., Goodman N., Roth R.A. Treatment of high-grade low-stage prostate cancer by high-dose-rate brachytherapy. J Endourol. 14:(4):2000;351-356.
8. Damore S.J., Syed N., Puthawala A.A., Sharma A. Needle displacement during HDR brachytherapy in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 46:(5):2000;1205-1211.
9. Demanes D.J., Rodriguez R.R., Altieri G.A. High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method. Radiother Oncol. 57:(3):2000;289-296.
10. Hanks G.E., Lee W.R., Hanlon A.L., et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or =10 NG/ML. Int J Radiat Oncol Biol Phys. 35:(5):1996;861-868.
11. Hanks G.E., Martz K.L., Diamond J.J. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 15:1988;1299-1305.
12. Hanks G.E., Schultheiss T.E., Hanlon A.L., et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys. 37:(3):1997;543-550.
13. Horwitz E.M., Winter K., Hanks G.E., Lawton C.A., Russell A.H., Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 49:(4):2001;947-956.
14. Hoskin P.J. High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. Radiother Oncol. 57:(3):2000;285-288.
15. King C.R., Mayo C.S. Is the prostate α/β ratio of 1.5 from Brenner and Hall a modeling artifact? Int J Radiat Oncol Biol Phys. 47:2000;536-537.
16. Kovacs G., Galalae R., Loch T., et al. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Onkol. 175:(Suppl. 2):1999;87-88.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
18. Landis S.H., Murray T., Bolden S., Wingo P.A. CA Cancer J Clin. 49:1999;8-31.
19. Lawton C.A., Won M., Pilepich M.V. Long term treatment sequelae following external beam irradiation for adenocarcinomas of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 21:1991;935-939.
20. Lee A.K., Schultz D., Renshaw A., Richie J., D'Amico A.V. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys. 49:2001;673-677.
21. Mantel N., Haenszel W. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. (58):1963;690-700.
22. Marks L.B., Anscher M.S. Radiotherapy for prostate cancer: should the seminal vesicles be considered target? Int J Radiat Oncol Biol Phys. 24:(3):1992;435-440.
23. Martinez A.A., Pataki I., Edmundson G., Sebastian E., Brabbins D., Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys. 49:2000;61-69.
24. Mate T.P., Gottesman J.E., Hatton J., Gribble M., Van Hollebeke L. High-dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys. 41:(3):1998;525-533.
25. Merrick G.S., Butler W.M., Dorsey A.T., Lief J.H., Walbert H.L., Blatt H.J. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 43:(5):1999;1021-1027.
26. Pilepich M.V., Bagshaw M.A., Asbell S.O., et al. Radical prostatectomy or radiotherapy in carcinoma of prostate: the dilemma continues. Urology. 30:1987;18-21.
27. Pollack A., Smith L.G., von Eschenbach A.C. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 48:(2):2000;507-512.
28. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:(5):1997;1011-1018.
29. Schultheiss T.E., Lee W.R., Hunt M.A., Hanlon A.L., Peter R.S., Hanks G.E. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 37:(1):1997;3-11.
30. Vicini F.A., Kestin L.L., Martinez A.A. Use of conformal high dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Tech Urol. 6:(2):2000;135-145.
31. Waterman F.M., Yue N., Reisinger S. Effect of the edema on the post implant dosimetry of an I-125 prostate implant: a case study. Int J Radiat Oncol Biol Phys. 38:1997;335-339.
32. Yeoh E.E.K., Botten R., Russo A., et al. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. Int J Radiat Oncol Biol Phys. 47:(4):2001;915-924.
33. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:(3):1998;491-500.
34. Zelefsky M.J., Leibel S.A., Kutcher G.J., Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol. 8:(2):1998;107-114.